

**DERMATOLOGY**

**PATIENT INFORMATION**

Name:		SSN:	DOB:	
Address:		City:	State:	Zip:
Home Phone:	Cell:	Email:	Height:	Weight:
				Gender: Female Male

**INSURANCE INFORMATION (or attach copy of the cards)**

Primary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:
Secondary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:

**CLINICAL INFORMATION**

Primary Diagnosis:  Moderate to Severe Plaque Psoriasis  Psoriatic Arthritis  Hidradenitis Suppurativa  Atopic Dermatitis  Alopecia Areata  Other: \_\_\_\_\_ Diagnosis Code (ICD-10): \_\_\_\_\_

Date of Diagnosis: \_\_\_\_\_ TB Test Completed On: \_\_\_\_\_ BSA: \_\_\_\_\_ Latex Allergy: Y N

**PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)**

<p><b>ADBRY<sup>®</sup></b> (<i>tralokinumab-ldrm</i>) 150 mg PFS  <input type="checkbox"/> Induction: Inject 600 mg (4 x 150 mg) SUBQ                  Qty: 4 Refills: None                  Maintenance:  <input type="checkbox"/> Inject 300 mg (2 x 150 mg) SUBQ every other week  <input type="checkbox"/> Inject 300 mg (2 x 150 mg) SUBQ every 4 weeks  <input type="checkbox"/> ADBRY<sup>™</sup> Bridge Care<sup>™</sup> Program:                  Inject 300 mg (2 x 150 mg) SUBQ every other week, starting on Day 15                  Qty: _____ Refills: _____</p> <p><b>AMJEVITA<sup>™</sup></b> (<i>adalimumab-atto</i>) PFS  <input type="checkbox"/> SureClick 40 mg/0.8 mL <input type="checkbox"/> PFS 20 mg/0.4 mL <input type="checkbox"/> PFS 40 mg/0.8 mL  <input type="checkbox"/> Induction: Inject 2 x 40 mg SUBQ  <input type="checkbox"/> Maintenance: 40 mg every other week starting 1 week after initial dose                  Qty: _____ Refills: _____</p> <p><b>BIMZELX<sup>®</sup></b> (<i>bimekizumab-bkzx</i>) PFS  <input type="checkbox"/> Bridge<sup>®</sup>  <input type="checkbox"/> Induction: Inject 320 mg (2 x 160 mg) SUBQ at week 0, 4, 8, 12, and 16                  Qty: 10 syringes Refills: _____  <input type="checkbox"/> Maintenance: Inject 320 mg (2 x 160 mg) SUBQ every 8 weeks                  Qty: 2 syringes Refills: _____</p> <p><b>CIBINQO<sup>™</sup></b> (<i>abrocitinib</i>) tablet  <input type="checkbox"/> 50 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 200 mg  <input type="checkbox"/> ____ mg PO once daily                  Qty: _____ Refills: _____</p> <p><b>Cimzia<sup>®</sup></b> (<i>certolizumab pegol</i>) PFS  <input type="checkbox"/> Induction: Inject 2 x 200 mg/mL SUBQ at week 0, 2, and 4                  Qty: 6 syringes Refills: 0                  Maintenance:  <input type="checkbox"/> 2 x 200 mg SUBQ every 4 weeks  <input type="checkbox"/> 2 x 200 mg SUBQ every 2 weeks  <input type="checkbox"/> 200 mg SUBQ every 2 weeks                  Qty: 28 days Refills: _____</p> <p><b>COSENTYX<sup>®</sup></b> (<i>secukinumab</i>)                  75 mg <input type="checkbox"/> PFS  <input type="checkbox"/> Induction: Inject 300 mg (2 x 150 mg/mL) SUBQ week 0, 1, 2, 3, 4                  Qty: 10 Refills: 0  <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ every 4 weeks                  Qty: 28 days Refills: _____                  150 mg <input type="checkbox"/> 150 mg Sensoready<sup>®</sup> Pen Kit <input type="checkbox"/> 150 mg PFS  <input type="checkbox"/> Induction: Inject 150 mg SUBQ week 0, 1, 2, 3, 4                  Qty: 5 Refills: _____  <input type="checkbox"/> Maintenance: Inject 150 mg SUBQ every 4 weeks                  Qty: 28 days Refills: _____                  300 mg <input type="checkbox"/> UnoReady Pen (1 x 300 mg/2 mL)  <input type="checkbox"/> Sensoready<sup>®</sup> Pen Kit (2 x 150 mL) <input type="checkbox"/> PFS (2 x 150 mL)  <input type="checkbox"/> Induction: Inject 300 mg SUBQ week 0, 1, 2, 3, 4                  Qty: 10 Refills: 0  <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ every 4 weeks                  Qty: 28 days Refills: _____  <input type="checkbox"/> Bridge<sup>®</sup></p> <p><b>DUPIXENT<sup>®</sup></b> (<i>dupilumab</i>) <input type="checkbox"/> PFS <input type="checkbox"/> pen  <input type="checkbox"/> Induction: Inject 2 x 300 mg (600 mg) SUBQ Day 1                  Qty: 2 for 14 days Refills: None  <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ every other week                  Qty: 2 for 28 days Refills: _____</p>	<p><b>EBGLYSS<sup>™</sup></b> (<i>lebrikizumab-ibkz</i>) <input type="checkbox"/> pen  <input type="checkbox"/> Initial: Inject 500 mg (2 x 250 mg) SUBQ at week 0 and 2                  Qty: 4 pens Refills: None  <input type="checkbox"/> Induction: Inject 250 mg SUBQ every 2 weeks (weeks 4-14)                  Qty: 2 pens Refills: 2  <input type="checkbox"/> Maintenance: Inject 250 mg SUBQ every 4 weeks starting week 16                  Qty: 1 pen Refills: _____</p> <p><b>ENBREL<sup>®</sup></b> (<i>etanercept</i>) <input type="checkbox"/> Mini Cartridge <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector <input type="checkbox"/> Vial  <input type="checkbox"/> Induction: Inject (50 mg) SUBQ twice weekly for three months                  Qty: 8 Refills: 2                  Maintenance: <input type="checkbox"/> 50 mg <input type="checkbox"/> 25 mg  <input type="checkbox"/> Once weekly SUBQ <input type="checkbox"/> Twice weekly SUBQ                  Qty: <input type="checkbox"/> 8 <input type="checkbox"/> 4 Refills: _____</p> <p><b>ERIVEDGE<sup>™</sup></b> (<i>vismodegib</i>)  <input type="checkbox"/> 150 mg capsule once daily PO, with or without food                  Qty: 28 days Refills: _____</p> <p><b>HUMIRA<sup>®</sup></b> (<i>adalimumab</i>)  <input type="checkbox"/> pen <input type="checkbox"/> PFS  <input type="checkbox"/> citrate free (CF) <input type="checkbox"/> original formula  <b>Hidradenitis Suppurativa Starter:</b>  <input type="checkbox"/> 160 mg SUBQ day 1, 80 mg SUBQ day 15  <input type="checkbox"/> 80 mg SUBQ day 1, 80 mg SUBQ day 2, 80 mg SUBQ day 15  <input type="checkbox"/> Psoriasis Starter: 80 mg SUBQ day 1, 40 mg SUBQ day 8, 40 mg SUBQ day 22                  Qty: 1 Pack Refills: 0  <b>Hidradenitis Suppurativa Maintenance:</b>  <input type="checkbox"/> 40 mg SUBQ once weekly, beginning day 29  <input type="checkbox"/> 80 mg SUBQ every other week, beginning day 29  <input type="checkbox"/> Psoriasis Maintenance: 40 mg SUBQ every other week                  Qty: 28 days Refills: _____</p> <p><b>ILUMYA<sup>™</sup></b> (<i>tildrakizumab-asnm</i>) PFS  <input type="checkbox"/> Induction: Inject 100 mg/mL SUBQ at weeks 0 and 4                  Qty: 2 Refills: None  <input type="checkbox"/> Maintenance: Inject 100 mg/mL SUBQ every 12 weeks                  Qty: _____ Refills: _____</p> <p><b>INFLECTRA<sup>®</sup></b> (<i>infliximab-dyyb</i>) 100 mg vials  <input type="checkbox"/> 3 mg/kg <input type="checkbox"/> 5 mg/kg <input type="checkbox"/> 10 mg/kg  <input type="checkbox"/> Induction: Give dose as an IV infusion at 0, 2, and 6 weeks                  Qty: _____ Refills: 2  <input type="checkbox"/> Maintenance: Give dose as an IV infusion every ____ weeks                  Qty: _____ Refills: 2</p> <p><b>LITFULO<sup>™</sup></b> (<i>ritlecitinib</i>) capsule <input type="checkbox"/> 50 mg PO once daily                  Qty: 28 Refills: _____</p> <p><b>NEMLUVIO<sup>®</sup></b> (<i>nemolizumab-ilt</i>) PFS <input type="checkbox"/> 30 mg/mL  <input type="checkbox"/> Induction: Inject 60 mg/mL (2 x 30 mg/mL) SUBQ                  Qty: 2 Refills: None  <input type="checkbox"/> Maintenance: Inject 30 mg/mL SUBQ every 4 weeks                  Qty: _____ Refills: _____</p> <p><b>ODOMZO<sup>®</sup></b> (<i>sonidegib</i>) capsule  <input type="checkbox"/> 200 mg on an empty stomach, at least 1 hr before or 2 hrs after a meal                  Qty: 30 Refills: _____</p> <p><b>OLUMIANT<sup>®</sup></b> (<i>baricitinib</i>) tablet  <input type="checkbox"/> 2 mg PO once daily <input type="checkbox"/> 4 mg PO once daily                  Qty: _____ Refills: _____</p> <p><b>OPZELURA<sup>®</sup></b> (<i>roxolitinib</i>) cream <input type="checkbox"/> 1.5% cream 60 gram tube                  Qty: ____ tubes Refills: 0                  Qty: 28 day supply</p>	<p><b>OTEZLA<sup>®</sup></b> (<i>apremilast</i>)  <input type="checkbox"/> Titration Pack: PO as directed per package instructions                  Qty: 1 Pack Refills: 0  <input type="checkbox"/> Bridge Pack: PO as directed per package instructions                  Qty: 1 Pack Refills: _____  <input type="checkbox"/> Maintenance: (30 mg) PO twice daily                  Qty: 30 days Refills: _____</p> <p><b>REMICADE<sup>®</sup></b> (<i>infliximab</i>) 100 mg vial <input type="checkbox"/> Biosimilar authorized  <input type="checkbox"/> Induction: 5 mg/kg as an IV infusion at 0, 2, and 6 weeks                  Qty: 1 dose Refills: 2  <input type="checkbox"/> Maintenance: 5 mg/kg as an IV infusion every 8 weeks                  Qty: _____ Refills: _____</p> <p><b>RINVOQ<sup>®</sup></b> (<i>upadacitinib</i>) extended-release tablet <input type="checkbox"/> 15 mg <input type="checkbox"/> 30 mg                  Once daily PO with or without food                  Qty: _____ Refills: _____</p> <p><b>SILIQ<sup>®</sup></b> (<i>brodalumab</i>) PFS  <input type="checkbox"/> Induction: Inject 210 mg SUBQ weeks 0 and 1                  Qty: 2 Refills: 0  <input type="checkbox"/> Maintenance: Starting at Week 2 of therapy, inject 210 mg SUBQ every 2 weeks                  Qty: 2 Refills: _____</p> <p><b>SIMPONI<sup>®</sup></b> (<i>golimumab</i>) <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector  <input type="checkbox"/> Inject 50 mg SUBQ once a month                  Qty: 1 Refills: _____</p> <p><b>SKYRIZI<sup>™</sup></b> (<i>risankizumab-rzaa</i>) <input type="checkbox"/> PFS <input type="checkbox"/> pen  <input type="checkbox"/> Inject 150 mg (1 injection) SUBQ at Week 0, Week 4                  Qty: 2 syringes Refills: _____  <input type="checkbox"/> Maintenance: Inject 150 mg SUBQ every 12 weeks                  Qty: _____ Refills: _____</p> <p><b>STELARA<sup>®</sup></b> (<i>ustekinumab</i>) <input type="checkbox"/> 45 mg PFS <input type="checkbox"/> 90 mg PFS  <input type="checkbox"/> Induction: Inject contents of 1 syringe SUBQ on day 0 and day 28                  Qty: 1 syringe Refills: 1  <input type="checkbox"/> Maintenance: Inject contents of 1 syringe SUBQ every 12 weeks                  Qty: 1 syringe Refills: _____</p> <p><b>SOTYKTU<sup>™</sup></b> (<i>deucravacitinib</i>) 6 mg tablet  <input type="checkbox"/> Once daily PO with or without food                  Qty: _____ Refills: _____</p> <p><b>TALTZ<sup>®</sup></b> (<i>ixekizumab</i>) <input type="checkbox"/> citrate free (CF) <input type="checkbox"/> Autoinjector <input type="checkbox"/> PFS  <input type="checkbox"/> Psoriasis Induction: Inject 160 mg (2 x 80 mg) SUBQ at week 0; Inject 80 mg at weeks 2, 4, 6, 8, 10, 12                  Qty: 8 Refills: 0  <input type="checkbox"/> Psoriatic Arthritis Induction: Inject 160 mg (2 x 80 mg) SUBQ at week 0                  Qty: 2 Refills: 0  <input type="checkbox"/> Maintenance: 80 mg SUBQ every 4 weeks                  Qty: 1 Refills: _____</p> <p><b>TREMFYA<sup>®</sup></b> (<i>guselkumab</i>) <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector  <input type="checkbox"/> Induction: Inject 100 mg SUBQ weeks 0 and 4                  Qty: 1 Refills: 1  <input type="checkbox"/> Maintenance: Inject 100 mg SUBQ every 8 weeks                  Qty: 1 Refills: _____</p> <p><input type="checkbox"/> OTHER                  STRENGTH:                  SIG/DIRECTIONS:                  QUANTITY: REFILLS:</p>
---	--	--

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution.  Dispense as written

**PHYSICIAN INFORMATION**

**Injection Training:**  Office to Instruct  SP to Arrange Teaching

Prescriber Name:	Phone:	Fax:
Office Contact:	Email:	
Address:	City:	State: Zip:
NPI #:	Tax ID#:	Ship To: <input type="checkbox"/> Patient <input type="checkbox"/> MD Office
Prescriber Signature:	Date:	